Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants

Sponsor
Hoffmann-La Roche
Study ID
NCT02536664
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

It is a non-interventional study with a duration of approximately 24 months per participant to investigate the therapeutic efficiency, safety and treatment regimens of Rituximab maintenance therapy in daily routine in participants with previously untreated, relapsed or refractory cluster of differentiation 20 (CD20)-positive follicular lymphoma (FL) in clinical practice.

Key Dates

Start date
Sep 30, 2009
Status verified
Mar 2023
Primary completion
Jun 30, 2014
Completion
Jun 30, 2014

Study Design

Enrollment
505 participants (actual)

Arms

  • Arm: First-line Stratum
    Participants who were untreated and decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
  • Arm: Relapsed/Refractory Stratum
    Participants who relapsed after treatment with chemotherapeutic regimens with or without Rituximab and were decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.

Primary Outcome Measure

Percentage of Participants Who Were Alive and Free From Progressive Disease [ Time Frame: 2 years ]

Related Studies